Markets

Eli Lilly Stock Surges as Weight Loss Drug Sales Drive Massive Earnings Beat

Pharmaceutical giant raises full-year outlook by $2 billion as Zepbound and Mounjaro prescriptions skyrocket, with 20,000 patients now taking new pill Foundayo.

Eli Lilly Stock Surges as Weight Loss Drug Sales Drive Massive Earnings Beat
Read the full reporting at CNBC Markets.

Originally reported by CNBC Markets.

Eli Lilly weight loss drugs Zepbound Mounjaro Foundayo earnings